Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : Medical Care successfully places USD bonds

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2019 | 03:49am EDT

Fresenius Medical Care, the world's largest provider of dialysis products and services, yesterday successfully placed bonds with an aggregate principal amount of USD 500 million. The bonds have a maturity of 10 years and an annual coupon of 3.750%. The issue price is 98.461%, resulting in a yield of 3.938%.

The proceeds will be used for general corporate purposes, including the refinancing of outstanding indebtedness.

Application will be made for admission to trading of the bonds on the regulated market of the Luxembourg Stock Exchange.

Disclaimer
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the 'United States') or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein have not been and will not be registered under U.S. Securities Act of 1933, as amended (the 'Securities Act') and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

This announcement has been prepared on the basis that any offer of Notes in any Member State of the European Economic Area (EEA) which has implemented the Prospectus Directive (2003/71/EC), as amended (each, a Relevant Member State) will be made pursuant to an exemption under the Prospectus Directive, as implemented in that Relevant Member State, from the requirement to publish a prospectus for offers of securities. Fresenius Medical Care AG & Co. KGaA has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius Medical Care AG & Co. KGaA or any other person to publish or supplement a prospectus for such offer.

This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order') or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as 'relevant persons'). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this announcement. In furnishing our website address in this announcement, we do not intend to incorporate any information on our website into this announcement.

Disclaimer

Fresenius SE & Co. KGaA published this content on 14 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2019 07:48:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO. KGAA
07/18CVS to Test a Device For Dialysis at Home -- WSJ
DJ
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/02FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
07/01FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
06/27FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/21FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/14FRESENIUS : Medical Care successfully places USD bonds
PU
06/12FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/11FRESENIUS : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Pr..
AQ
More news
Financials (EUR)
Sales 2019 35 372 M
EBIT 2019 4 641 M
Net income 2019 1 883 M
Debt 2019 19 742 M
Yield 2019 1,78%
P/E ratio 2019 13,4x
P/E ratio 2020 12,5x
EV / Sales2019 1,27x
EV / Sales2020 1,17x
Capitalization 25 200 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,64  €
Last Close Price 45,26  €
Spread / Highest target 56,8%
Spread / Average Target 25,2%
Spread / Lowest Target -28,3%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors